4,4',5,5'-tetrabromo-2,2'-bi-1H-imidazole | 98138-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4,4',5,5'-tetrabromo-2,2'-bi-1H-imidazole
• 英文别名: 4,4',5,5'-tetrabromo-2,2'-biimidazole；4,5,4',5'-tetrabromo-1H,1'H-[2,2']biimidazolyl；4,5,4',5'-Tetrabrom-1H,1'H-[2,2']biimidazolyl；4,5-dibromo-2-(4,5-dibromo-1H-imidazol-2-yl)-1H-imidazole
• CAS: 98138-00-2
• 化学式: C₆H₂Br₄N₄
• 分子量: 449.725
• InChiKey: ZPPZZFKNGUKQSW-UHFFFAOYSA-N

物化性质

• 沸点：
  639.1±65.0 °C(Predicted)
• 密度：
  2.766±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,4',5,5'-tetrabromo-2,2'-bi-1H-imidazole 、 3,5-二叔丁基苯胺 反应 168.0h， 以45%的产率得到N,N'-bis(3,5-di-tert-butylphenyl) oxamide
  参考文献：
  名称：

  Crossley, Maxwell J.; Gorjian, Sargon; Sternhell, Sever, Australian Journal of Chemistry, 1994, vol. 47, # 4, p. 723 - 738

  摘要：

  DOI：
• 作为产物：
  描述：

  联咪唑 在 溴 、 sodium acetate 、 溶剂黄146 作用下， 生成 4,4',(5,5')-dibromo-2,2'-bi-1H-imidazole 、 4,4',5,5'-tetrabromo-2,2'-bi-1H-imidazole
  参考文献：
  名称：

  Influence of Fat-Free Mass and Functional Status on Resting Energy Expenditure in Underweight Elders

  摘要：

  Background. In underweight elders, resting energy expenditure (REE) and its relationship with fat-tree mass (FFM) could be modified by sarcopenia. physical activity, and functional limitation. The aims Of this study were to investigate REE and its relationship with quantity and metabolic activity of FFM and to evaluate the influence of functional status oil REE ill underweight elderly subjects.Methods. Forty-eight underweight elders (BMI < 20) and 54 normal Weight elderly subjects (BMI 20-30) as a control group were selected. Body composition was determined by dual energy x-ray absorptiometry (DEXA). REE was measured by indirect calorimetry. Ability in activities of daily living, (ADLs) was assessed by the Katz index.Results. Underweight elders had significantly lower FFM. FFM index (FFM/height(2)), and REE than healthy Subject. REE adjusted for FFM with analysis of covariance remained significantly lower in the underweight group (1287 +/- 85 vs 1715 +/- 139 kcal/day in men, and 1124 +/- 63 vs 1366 +/- 91 kcal/day in women). Katz index in the underweight group was inverselv correlitted with REE (r = -0.68: p < .001) cven ittfei removid of FFNI. IFNI, and gender, by multiple regression analysis. In this model, FFM and Katz index together explained approximately 54% of REE variability.Conclusions. Underweight elderly subjects show it hypometabolism due to a reduction of both FFM quantity and its metabolic activity. Functional status in ADLs comes out its an important predictor of REE independently from FFM. The limited physical activity might be the underlying determinant of this hypometabolism, but further investigations are necessary to confirm this issue.

  DOI：

  10.1093/gerona/57.5.m302

文献信息

• Kuhn; Blau, Justus Liebigs Annalen der Chemie, 1957, vol. 605, p. 32,34
  作者：Kuhn、Blau

  DOI：——

  日期：——
• Imidazole Derivatives and Their use as Dopants for Doping an Organic Semiconductor Matrix Material
  申请人：Hartmann Horst

  公开号：US20100301277A1

  公开（公告）日：2010-12-02

  The present invention relates to imidazole derivatives and their use as dopants for doping an organic semiconductor matrix material, organic semiconductor materials and electronic or optoelectronic structural elements.
• US8460581B2
  申请人：——

  公开号：US8460581B2

  公开（公告）日：2013-06-11
• [EN] 2,7,12,17 ALKENYL, ARYL AND HETEROARYL DERIVED FROM 3,6,13,16-TETRAAZAPORPHYCENE, METHOD, INTERMEDIATE COMPOUND AND CORRESPONDING UTILIZATIONS<br/>[ES] 2,7,12,17 ALQUENIL, ARIL Y HETEROARIL DERIVADOS DEL 3,6,13,16-TETRAAZAPORFICENO, Y PROCEDIMIENTO, COMPUESTO INTERMEDIO Y UTILIZACIONES CORRESPONDIENTES<br/>[FR] 2,7,12,17 ALCENYLE, ARYLE ET HETEROARYLE DERIVES DU 3,6,13,16-TETRAAZAPORPHYCENE ET PROCEDE, COMPOSE INTERMEDIAIRE ET UTILISATIONS CORRESPONDANTES
  申请人：INST QUIMIC DE SARRIA CETS

  公开号：WO2003104237A1

  公开（公告）日：2003-12-18

  La presente invención desarrolla la síntesis novedosa de nuevos sistemas 3,6,13,16-tetraazaporficénicos de fórmula general (1) donde R puede ser un grupo alquenilo (vinilo o estirilo), o un grupo arilo el cual puede estar no sustituido o sustituido por uno o varios grupos alquilo C1-6, alcoxilo C1-6, amino, mono- o dialquilamino o hydroxicarbonilo, o un grupo arilo substituido por p-CH3(OCH2CH2)nOCH2- , donde n es un numero entero comprendido entre 1 y 6, o un grupo heteroarilo (tienilo o piridilo) el cual puede estar no sustituido o sustituido por uno o más grupos alquilo C1-6, incluyendo un nuevo producto intermedio.